Back to Results

CDT Equity Inc (CDT)

CDT Equity Inc. is a NASDAQ-listed common stock company in the healthcare sector focused on clinical-stage specialty biopharmaceutical development. The company is working on pharmaceutical products aimed at unmet needs in autoimmune diseases and idiopathic male infertility. Its development pipeline includes AZD1656, which has completed Phase I testing across several indications, including type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor, as well as AZD5904, which has completed Phase I clinical trials for idiopathic male infertility. CDT Equity also has a strategic services agreement with Agility Life Sciences to support the development of new solid oral-dosage form products. The company was founded in 2019, is based in Naples, Florida, and adopted its current name in August 2025 after previously operating as Conduit Pharmaceuticals Inc.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-CDT
$3.56
-3.5% Downside
Fair
—
—
—
Weak
—
—
—
0.0%
August 13, 2026
-0.1x
0.0x
—
2.25 M
3.122 M
27.5%
62.9%
-1.6
—
35.1%
Valuation • Fair Value

CDT Equity Inc (NASDAQ-CDT) Fair Value by Valuation Model

Compare the primary fair value estimate for CDT Equity Inc (NASDAQ-CDT) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$3.56

Estimated downside of 3.5% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$3.56

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for CDT Equity Inc (NASDAQ-CDT) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for CDT Equity Inc (NASDAQ-CDT)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-24.426 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review CDT Equity Inc (NASDAQ-CDT) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for CDT Equity Inc (NASDAQ-CDT)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

3

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-1.6

Lower score that deserves closer risk review.

FCF / Net Income

35.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for CDT Equity Inc (NASDAQ-CDT). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for CDT Equity Inc (NASDAQ-CDT)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 13, 2026

Days to Earnings

23

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for CDT Equity Inc (NASDAQ-CDT), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

CDT Equity Inc (NASDAQ-CDT) Stock Forecast & Technical Outlook

Review CDT Equity Inc (NASDAQ-CDT) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for CDT Equity Inc (NASDAQ-CDT) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for CDT Equity Inc (NASDAQ-CDT) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for CDT Equity Inc (NASDAQ-CDT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for CDT Equity Inc (NASDAQ-CDT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for CDT Equity Inc (NASDAQ-CDT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for CDT Equity Inc (NASDAQ-CDT)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for CDT Equity Inc (NASDAQ-CDT) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

CDT Equity Inc (NASDAQ-CDT) Stock FAQ

Quick answers about CDT Equity Inc (NASDAQ-CDT) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$3.56
Estimated downside 3.5%
Valuation Rating
Overvalued
Estimated downside of 3.5%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Weak
Current financial-health read

The current fair value estimate for CDT Equity Inc (NASDAQ-CDT) is $3.56. This implies an estimated downside of 3.5% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 3.5% versus the current market price.

An analyst price target for CDT Equity Inc (NASDAQ-CDT) is not currently available in the latest data file.

The current financial health read for CDT Equity Inc (NASDAQ-CDT) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for CDT Equity Inc (NASDAQ-CDT) is August 13, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for CDT Equity Inc (NASDAQ-CDT) is -0.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for CDT Equity Inc is 2.25 M.

The current enterprise value listed for CDT Equity Inc is 3.122 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for CDT Equity Inc is NASDAQ-CDT, and the stock is listed on NASDAQ.

CDT Equity Inc (NASDAQ-CDT) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for CDT Equity Inc is 27.5%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for CDT Equity Inc is 62.9%. Free float helps investors understand how much of the share base is available for public trading.

Similar Life Sciences Tools & Services Stocks on NASDAQ View more

Illumina Inc (ILMN) Illumina Inc (ILMN)
Medpace Holdings Inc (MEDP) Medpace Holdings Inc (MEDP)
ICON PLC (ICLR) ICON PLC (ICLR)
Bio-Techne Corp (TECH) Bio-Techne Corp (TECH)
Tempus AI Inc (TEM) Tempus AI Inc (TEM)
Bruker Corporation (BRKR) Bruker Corporation (BRKR)
Repligen Corporation (RGEN) Repligen Corporation (RGEN)
10X Genomics Inc (TXG) 10X Genomics Inc (TXG)
Sotera Health Co (SHC) Sotera Health Co (SHC)
Adaptive Biotechnologies Corp (ADPT) Adaptive Biotechnologies Corp (ADPT)
Maravai Lifesciences Holdings Inc (MRVI) Maravai Lifesciences Holdings Inc (MRVI)
Abcellera Biologics Inc (ABCL) Abcellera Biologics Inc (ABCL)
Fortrea Holdings Inc (FTRE) Fortrea Holdings Inc (FTRE)
BioLife Solutions Inc (BLFS) BioLife Solutions Inc (BLFS)
Personalis Inc (PSNL) Personalis Inc (PSNL)
Azenta Inc (AZTA) Azenta Inc (AZTA)
Cryoport Inc (CYRX) Cryoport Inc (CYRX)
Evotec SE ADR (EVO) Evotec SE ADR (EVO)
Cytek Biosciences Inc (CTKB) Cytek Biosciences Inc (CTKB)
Mesa Laboratories Inc (MLAB) Mesa Laboratories Inc (MLAB)
Pacific Biosciences of California (PACB) Pacific Biosciences of California (PACB)
Standard Biotools Inc (LAB) Standard Biotools Inc (LAB)
OmniAb Inc (OABI) OmniAb Inc (OABI)
Alpha Teknova Inc (TKNO) Alpha Teknova Inc (TKNO)